Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propacetamol is a water-soluble, parenteral prodrug of paracetamol (acetaminophen), formed by the esterification of paracetamol with diethylglycine. It is used intravenously or intramuscularly for the management of pain and fever, particularly in post-operative care or when oral/rectal administration is not possible and NSAIDs are contraindicated. After administration, propacetamol is rapidly hydrolyzed in plasma to release active paracetamol. The mechanism of action mirrors that of paracetamol, primarily involving inhibition of prostaglandin synthesis via cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes under low peroxide conditions. Paracetamol’s analgesic effect also involves central mechanisms such as serotonergic pathways, L-arginine/nitric oxide pathway modulation, cannabinoid system involvement, and redox mechanisms[1][2][6]. Propacetamol has been widely used outside the United States since 1985[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propacetamol.